Pramipexole Use in Patients with Frontotemporal Dementia and Parkinson's Symptoms

Key Safety Concerns

• Elderly patients with cognitive impairment have a significantly increased risk of hallucinations with pramipexole compared to younger patients 1
• The American Academy of Sleep Medicine warns that dopaminergic agonists may exacerbate symptoms of dementia with Lewy bodies (DLB), and this concern extends to other dementia syndromes including FTD 2

Neuropsychiatric Adverse Effects

• Pramipexole carries substantial risk for negative impulsive behaviors including pathological gambling, hypersexuality, and compulsive shopping 1
• These behavioral complications are particularly problematic in FTD patients who already have impaired executive function and impulse control 2

Monitoring Parameters

• If dopaminergic therapy is essential, monitor closely for blood pressure (orthostatic hypotension risk) 1
• Monitor motor symptoms and response 1
• Monitor sedation level and fall history 1
• Monitor behavioral changes and impulse control disorders 1
• Monitor hallucinations and psychotic symptoms 1

Clinical Context

• The American Academy of Sleep Medicine notes that efficacy of pramipexole in REM sleep behavior disorder appears limited to patients who have not yet developed neurodegenerative disease 2